Check-Cap (NASDAQ:CHEK) Now Covered by Analysts at StockNews.com

Investment analysts at StockNews.com began coverage on shares of Check-Cap (NASDAQ:CHEK) in a note issued to investors on Friday. The brokerage set a “sell” rating on the medical research company’s stock.

Check-Cap Stock Performance

Shares of CHEK stock opened at $1.10 on Friday. The company has a market capitalization of $6.44 million, a PE ratio of -0.37 and a beta of 0.25. Check-Cap has a 52-week low of $0.56 and a 52-week high of $3.45. The business’s fifty day moving average is $0.96 and its 200 day moving average is $1.54.

About Check-Cap

Check-Cap Ltd., a clinical stage medical diagnostics company, engages in the development of a capsule-based screening technology that utilizes ultra-low-dose X-rays to scan the inner lining of the colon for precancerous polyps, and other structural abnormalities in Israel. Its C-Scan system consists of C-Scan Cap, an X-ray scanning capsule for detection of suspected polyps; C-Scan Track, a disposable system attached to the patient's back through biocompatible adhesive skin patches; and C-Scan View software, a client/server-based application that enables procedure data download from the C-Scan Track, data analysis, and report generation.